Latest Information Update: 02 Aug 2006
At a glance
- Originator Merck & Co
- Class Class III antiarrhythmics
- Mechanism of Action Calcium channel antagonists; Potassium channel antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Arrhythmias
Most Recent Events
- 02 Aug 2006 Discontinued - Preclinical for Arrhythmias in USA (unspecified route)
- 09 Sep 1997 New profile
- 09 Sep 1997 Preclinical development for Arrhythmias in USA (Unknown route)